⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0368

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2023-05-09
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

severe serious assessed 2026-08-18

Grade 4 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-06-05 (study day 17); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-08-19 (study day 92); relationship: N

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-28 (study day 223); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-04 (study day 230); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-02-01 (study day 258); relationship: N

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-18 (study day 275); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-10 (study day 296); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-04-03 (study day 320); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-05-22 (study day 369); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.